Suprachoroidal Injection and Beyond: Exploring Advanced Administration Routes for Ocular Diseases

Dear Colleagues,

I am pleased to announce that we are now welcoming submissions for a new Special Issue, entitled "Suprachoroidal Injection and Beyond: Exploring Advanced Administration Routes for Ocular Diseases".

The management and treatment of posterior segment and retinal diseases continue to pose significant challenges given the robust barriers within the ocular anatomy that limit the bioavailability and delivery of medications. Current approaches, often involving frequent dosing via eye drops or intravitreal injections, tend to exhibit significant side effects over the long term.

This Special Issue aims to explore advanced administration routes, with a spotlight on the suprachoroidal injection technique. As a novel form of targeted drug delivery to the posterior segment, it provides potential benefits such as an extended duration of action and improved bioavailability. Furthermore, the minimized risk of corticosteroid-related adverse events, such as cataracts and intraocular pressure elevation, as a result of compartmentalization, underlines the significant potential of this technique.

We are particularly interested in studies that explore the potential of suprachoroidal injection in conjunction with biotech products, and gene- and cell-based therapies. Submissions that demonstrate these combined approaches through both preclinical and clinical studies are highly encouraged. There is significant anticipation that these integrative strategies could lead to personalized treatments. We also encourage submissions that not only focus on suprachoroidal injections but also highlight other advanced routes of administration, their development, and their clinical implications. The objective is to curate a comprehensive panorama of the latest, most innovative technologies and techniques that enhance the safety and efficiency of drug delivery in the field of ophthalmology.

I am inviting you to submit your high-quality research and review articles that align with the theme of this Special Issue. We eagerly anticipate your contributions, which we believe will not only deepen the understanding of the potential of advanced administration routes, including suprachoroidal injections, but also have the potential to translate into patient-centred solutions that can greatly improve the quality of life for individuals battling posterior segment and retinal diseases.

Prof. Dr. Francisco Javier Otero-Espinar
Dr. Kevin Yang Wu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• suprachoroidal injection
• advanced administration routes
• ocular diseases
• posterior segment diseases
• retinal diseases
• advanced drug delivery
• intravitreal injections
• corticosteroid-related adverse events
• biotech products in ophthalmology
• gene and cell-based therapies
• personalized treatments
• gene-based therapy
• cell-based therapy
• preclinical and clinical studies
• duration of action